Kinase drug discovery approaches in chronic myeloproliferative disorders (Q37472874)

20 August 2017

1 reference

title

Kinase drug discovery approaches in chronic myeloproliferative disorders (English)

1 reference

20 August 2017

1 reference

C Kumar

1

1 reference

20 August 2017

A V Purandare

series ordinal

2

1 reference

20 August 2017

F Y Lee

series ordinal

3

1 reference

20 August 2017

M V Lorenzi

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

4 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

28

1 reference

20 August 2017

issue

24

1 reference

20 August 2017

page(s)

2305-2313

1 reference

Primary myelofibrosis: update on definition, pathogenesis, and treatment.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Monitoring treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

New and old treatment modalities in primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

How I treat patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Indications for imatinib mesylate therapy and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Crucial role of Jak3 in negative selection of self-reactive T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Making progress through molecular attacks on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Medical management of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Applying the discovery of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Introduction to ‘A special spotlight review series on BCR–ABL-negative myeloproliferative neoplasms’

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.107

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.107

1 reference

20 August 2017

1 reference